Posted inBiotechnology
Reproductive Barriers in Dactylorhiza: Hybridization Insights
In a groundbreaking study that illuminates the complexities of plant reproduction, researchers have delved deep into the hybridization mechanisms and…
Posted inBiotechnology
Sex Differences in Social Health Drivers and Interventions
In a groundbreaking study published in the journal “Biology of Sex Differences,” researchers have embarked on a pioneering examination of…
Posted inBiotechnology
Global Urban Visual Perception: Demographics and Personality Differences
In an era where urban landscapes are continuously evolving, understanding how people perceive these environments has never been more essential.…
Posted inBiotechnology
AI Predicts Liver Cancer Invasion via MRI
In a groundbreaking advancement that could reshape the future of hepatocellular carcinoma (HCC) treatment, scientists have developed an innovative deep…
Posted inBiotechnology
Long-Read Metagenomics Tracks Strains Post-Transplant
In recent years, the field of microbiome research has witnessed remarkable progress, particularly in the context of faecal microbiota transplantation…
Posted inBiotechnology
Accessing Bay Area Hospitals After Major Hayward Quake
In the wake of an unprecedented seismic event, the San Francisco Bay Area faces a multifaceted challenge that extends beyond…
Posted inBiotechnology
Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety…
Posted inBiotechnology
Sanofi’s $1.7B rare disease bet beats CSL’s Zemaira in phase 2 face-off
Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. In a midstage study, efdoralprin…
Posted inBiotechnology
Ipsen writes check worth up to €1B to acquire next-gen cancer biotech
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy in a deal worth up to…
Posted inBiotechnology
Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets
Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) $10.2 billion in…